Literature DB >> 34662182

Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital.

Fernando J Diggs1, Jonathan D Edwards1, Kimberly B Garza2, Ali A M Hassoun3, Spencer H Durham4.   

Abstract

Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10 mg/kg based on total body weight but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750 mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing.

Entities:  

Keywords:  capped dosing; telavancin

Mesh：

Substances：

Year:  2021        PMID： 34662182      PMCID： PMC8765302          DOI： 10.1128/AAC.01603-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  8 in total

1.  Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Authors:  Kristen L Bunnell; Manjunath P Pai; Monica Sikka; Susan C Bleasdale; Eric Wenzler; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  Telavancin: a novel lipoglycopeptide antibiotic.

Authors:  Lisa Charneski; Priti N Patel; Donna Sym
Journal:  Ann Pharmacother       Date:  2009-04-28       Impact factor: 3.154

Review 3.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

4.  Population pharmacokinetics of telavancin in healthy subjects and patients with infections.

Authors:  Emil Samara; Jeng-Pyng Shaw; Steven L Barriere; Shekman L Wong; Philip Worboys
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Acute renal insufficiency during telavancin therapy in clinical practice.

Authors:  Luis A Marcos; Bernard C Camins; David J Ritchie; Ed Casabar; David K Warren
Journal:  J Antimicrob Chemother       Date:  2011-12-15       Impact factor: 5.790

6.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

Review 7.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

8.  Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Authors:  Ethan Rubinstein; Tahaniyat Lalani; G Ralph Corey; Zeina A Kanafani; Esteban C Nannini; Marcelo G Rocha; Galia Rahav; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Patrick C Lee; Arnold L Lentnek; Carlos M Luna; Jean-Yves Fagon; Antoni Torres; Michael M Kitt; Fredric C Genter; Steven L Barriere; H David Friedland; Martin E Stryjewski
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.